Enanta Pharmaceuticals, Inc. (ENTA) has a consensus analyst rating of Buy, based on 19 analysts covering the stock. Of those, 14 recommend buying, 3 recommend holding, and 2 recommend selling.
The analyst consensus price target for ENTA is $48.20, representing a +229.5% upside from the current price of $14.63. Price targets range from a low of $20.00 to a high of $87.00.
